Objective: To perform a clinical and genetic study of two large Italian families showing the cardinal clinical features of Silver syndrome (SS), a rare dominantly inherited form of hereditary spastic paraplegia (HSP) complicated by amyotrophy of the small hand muscles.
study has demonstrated that mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2, seipin) gene resulted in SPG17-SS or in distal hereditary motor neuropathy type V (dHMN V). 7 Furthermore, genetic heterogeneity has been shown in SS. 6, 8 In the current investigation, we mapped a novel HSP locus (SPG38) on chromosome 4p16-p15 in a large Italian family (RM- 36) showing the cardinal clinical features of SS. The SPG38 interval was restricted to 13.1-cM with D4S432 and D4S1599 as flanking markers. In addition, our report also demonstrates a novel SPG4 mutation in another large unrelated Italian pedigree (RM-51) which presents a clinical phenotype characterized by supplementary neurologic features in addition to typical clinical manifestations of SS.
METHODS Clinical assessment. This study was performed according to a protocol reviewed and approved by the Ethics Committee of the Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia, Rome, Italy. Blood samples were taken with informed consent from family members for DNA extraction. Individuals were interviewed and examined neurologically by at least one of the authors (A.O., G.B.). The neurologic assessment, including the age at examination and the age at onset, was carried out as previously described. 9, 10 The presence or absence of additional symptoms associated with HSP and the age at which these abnormalities appeared was carefully assessed following an accurate protocol that included a full medical history and examination, with detailed neurophysiologic, neuropsychological, and neuroimaging evaluations.
The electrophysiologic studies consisted of motor nerve conduction studies (mNCS) of the median, ulnar, and peroneal nerves (MN, UN, and PN) including F-wave analysis, sensory nerve conduction studies (sNCS) of the MN, UN, and sural nerve (SN), motor evoked potentials (MEPs) to the first dorsal interosseus muscle (FDI) and tibialis anterior muscle (TA), EMG of the upper and lower extremities, tongue, and sternocleidomastoid muscle (SCM), somatosensory evoked potentials (SSEPs) obtained from stimulation of the MN and tibial nerve (TN), and EEG. All neurophysiologic evaluations were performed using standard techniques. [11] [12] [13] [14] [15] Evaluation of cognitive functions including the diagnosis of mild cognitive impairment (MCI) followed research diagnostic criteria which have previously been described. 16, 17 All individuals with a complaint of defective memory were assessed with the new learning subscale of the Cambridge Cognitive Examination (CAMCOG), 18 which had been previously proved to be sensitive to cognitive dysfunctions in HSP. [19] [20] [21] Brain MRI studies were carried out following a rigorous protocol (details are available upon request). Diagnosis of hippocampal sclerosis (HS) was carried out by a visual analysis, using both primary (hippocampus atrophy, T2 signal hyperintensity, and loss of internal hippocampal architecture) and secondary findings (thinning of the fornix, mammillary body atrophy, and temporal horn dilatation). 22 Molecular genetic studies. Initially, linkage of SS in the RM-36 family (figure 1) to any of the known ADHSP loci (SPG3A, SPG4, SPG6, SPG7, SPG8, SPG9, SPG10, SPG12, SPG13, SPG19, SPG29, SPG31, and SPG33) and in the SPG17 locus was excluded by two-point logarithm of odds (lod) score analysis (data not shown). Disease-causing mutations in SPG4 and in BSCL2 were also excluded in two patients of the RM-36 family (III-9 and III-19) by direct sequencing of the coding regions for each of these genes (including at least 50 bases of intronic sequence), using previously described methods. 9, 21 In the same family, we then performed a genome-wide screening following earlier reports. 10 Two-point lod scores were determined with the FASTLINK version of the MLINK program. 23 For linkage computations, the disease allele was given a frequency of 10 Ϫ4 , the inheritance was considered AD, and male and female recombination rates () were assumed to be equal. The map order and distances between markers were based on the microsatellite-marker map of the Center for Medical Genetics, Marshfield Medical Research Foundation, Marshfield, WI (http://research.marshfieldclinic.org/genetics/). Physical sizes are according to human reference sequences of the National Centre for Biotechnology Information (NCBI) build 36.2 (http://www.ncbi.nlm. nih.gov/mapview/). A nominal phenocopy risk of 10 Ϫ4 was assumed, following previously described linkage analysis methods in SS. 6 Marker allele frequencies were calculated by genotyping a panel of 500 unrelated Italian individuals. GENEHUNTER-PLUS (http://www.stat.uchicago.edu/ genehunterplus/) 24 was used to identify and remove probable genotype errors and perform whole chromosome multipoint linkage analysis. After linkage was established to the new SPG38 locus, additional markers were genotyped in that chromosomal region and haplotype construction, assuming minimal recombination, was performed. Candidate genes were selected from the NCBI Human Genome Resources (http://www.ncbi.nlm.nih.gov/genome/guide/human/). Moreover, linkage studies at the currently known ADHSP loci were performed in the RM-51 family and sequence analyses of SPG4 were carried out in the proband of the pedigree (III-2) (figure 2). To prove whether the mutation segregates with the disease phenotype, PCR-restriction fragment length polymorphism (RFLP) analysis was performed using the restriction enzyme BsmFI.
RESULTS Clinical report. The clinical data for both families are reported in table e-1 on the Neurology ® Web site at www.neurology.org.
Family RM-36. This family contained 19 definitely affected individuals and an AD mode of inheritance was apparent with patients spanning four successive generations (figure 1). Age at onset was early both in lower limbs and in upper limbs with a mean Ϯ SD of 16.8 Ϯ 4.3 years and 18.5 Ϯ 4.5 years. Age at onset is given in table e-1. Spastic gait was the presenting symptom of the disease in all patients and was predominantly caused by mild to severe spasticity in the lower limbs and occasionally by additional weakness of the foot extensor. All patients had pyramidal tract signs consisting of hyperreflexia, extensor plantar responses, or both. Upon examination, Individuals II-5 and III-14 were using a cane and Individual II-8 was wheelchair-bound. Pes cavus was almost constantly present. All affected individuals apart from two (III-17 and IV-10) had unior bilateral wasting of the small hand muscles, which was primarily distributed to the thenar and dorsalis interosseus I muscles. The involvement of the hands was severe in two patients (II-13 and III-14) and always started later or at the same time with stiffness in the legs. In none of the affected individuals did the disease start or prevail in the hands. Mild to moderate weakness of the foot extensors was found in three patients (II-8, III-5, and IV-8). Sensation was generally normal, but a moderately impaired vibration sensation in ankles was referred in two affected individuals (II-3 and III-9). Two patients (II-5 and III-14) reported weakness and hyperreflexia of the upper limbs; however, Hoffmann sign was not described in any of the affected individuals. Atrophy of the tongue, peroneal muscle wasting, sphincter disturbances, cognitive dysfunctions, seizures, and sensory loss were absent.
Electrophysiologic study (NCS/EMG). Electrophysiology revealed the implication of lower motor neurons (LMNs) in addition to upper motor neurons (UMNs) with motor nerve conduction 
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Pedigree of the RM-51 family with segregation of the SPG4 mutation velocities varying from normal to slightly slowed although amplitudes of the compound muscle action potentials (CMAPs) ranged widely between severely reduced and normal depending on the degree of wasting of the thenar muscles (data not shown). Nevertheless, a divergence between abnormalities of the MN and UN was reported, since all neurophysiologic values of the ulnar motor nerve were normal apart from sporadically slightly reduced amplitudes. Central motor conduction time (CMCT) to FDI was normal in all patients but one (II-8). CMCT to the TA was prolonged in all patients. Needle EMG performed in 10 patients (I-1, II-5, II-8, II-13, III-5, III-9, III-14, IV-4, IV-6, and IV-8) identified chronic neurogenic variations most apparent distally and absence of active denervation. In all the affected individuals, no abnormal findings were detected by EMGs of the tongue and SCM. Autoptic data were not available. Atrophy of the tongue, sphincter disturbances, and sensory loss were absent; however, additional clinical features were present, including impaired vibration sensation, pes cavus, temporal lobe epilepsy (TLE), and cognitive dysfunctions (tables e-1 and e-2). Impairment of vibration sense in the ankles or in the ankles and knees was reported in all pa-tients but two (II-1 and II-9); pes cavus was always present (table e-1). Conversely, sensory symptoms such as paresthesias or ataxia and LMN symptoms such as muscle twitching or cramps were absent in all affected individuals. Autoptic studies were not obtainable.
Electrophysiologic study (NCS/EMG/SSEPs/EEG).
Neurophysiologic analyses showed normal sensory findings, but low amplitudes of CMAPs with only normal or mild slowed velocities (data not shown). Similarly to the results obtained in the RM-36 family, the CMAPs ranged extensively between severely reduced and normal depending on the degree of wasting of the thenar or peroneal muscles and the same kind of difference between anomalies of the MN and UN were detected, since all electrophysiologic values of the ulnar motor nerve were normal with the exception of occasionally slightly reduced amplitudes. Needle EMG carried out in eight patients (III-2, III-8, III-10, III-13, III-15, IV-1, IV-4, and IV-7) showed evidence of chronic denervation in distal muscle and absence of active denervation. In all affected individuals, no denervation signs were identified by EMGs of the tongue or SCM. In the same individuals the SSEPs were normal upon stimulation of the MN, whereas upon stimulation of the TN 11 out of 15 were found to be normal. The anomalies in four patients (III-2, III-8, IV-4, and IV-7) were minor, irrelevant, and confined to the lower limbs. All patients but one (IV-4) had had TLE with partial complex seizures since early childhood and there were no family members with TLE who did not have HSP. The seizures were always preceded by an aura which included olfactory and gustatory hallucinations, alteration of visual perceptions (micropsia, macropsia), and distortions of memory (déjà vu, jamais vu). In all patients with TLE the interictal EEG usually showed anterior or midtemporal spikes and superficial/sphenoidal electrodes were occasionally necessary for their detection. Other changes included intermittent or persisting slow activity over the temporal lobes. The EEG signs were unilateral or bilateral. Three affected individuals (II-7, III-2, and III-13) had weakness and hyperreflexia of the upper limbs, although Hoffmann sign was not described in any of the patients.
Neuropsychological evaluation. Neuropsychological assessments showed a MCI with CAMCOG scores between 63 and 68 in the affected individuals of the first, second, and third generations (table e-2). Brain imaging. Brain MRI studies in individuals with cognitive dysfunctions showed cortical atro-phy at the frontal or frontotemporal regions, which was correlated with the degree of cognitive impairment (table e-2). Besides, brain MRI showed at least one of the primary neuroradiologic signs indicative of HS in all the affected individuals with TLE ( figure 3 and table e-2).
Detection of SPG38 locus in the RM-36 family.
Negative or nonsignificant lod scores at all recombination fractions tested were obtained by genotyping every marker of the HD5 panel, apart from five microsatellite markers on chromosome 4p and one on chromosome 16 (two-point lod score Ͼ 1.0). The marker density was locally increased by testing all pedigree members with two additional markers and haplotypes were created. The candidate locus on chromosome 16 was clearly excluded from linkage (two-point lod score Ͻ Ϫ2.0). Furthermore, haplotype construc-tion showed different haplotypes segregating in the affected individuals. On the other hand, all genotyped markers on chromosome 4p candidate region produced significant two-point lod scores (Z max ϭ 3.30 at D4S2935), providing indication of linkage between the disease and this region. Multipoint analysis provided additional support for the localization of SS-predisposing locus to chromosome 4p (figure 4) and the haplotype structure showed that all affected family members had inherited an identical region between D4S432 and D4S1599 ( figure 1) . The upper and lower confines of the region were determined by recombination events identified in individuals II-13 and III-12 between markers D4S432 and D4S3023 (telomeric end) and between markers D4S2949 and D4S1599 (centromeric end). Recombination events across this region locate the disease locus (which we have termed SPG38 in accordance with HUGO nomenclature, http://www.genenames. org/) within a 13.1-cM interval, physical distance of approximately 6,906 kb. Previous cytogenetic localization of markers placed this locus on chromosome 4p16-p15 (NCBI, http://www.ncbi.nlm. nih.gov/mapview/). Database searches demonstrated that there are at least 84 transcripts mapped within the SPG38 region, including hypothetical transcripts.
Identification of a new mutation in SPG4 in the RM-51 family. Significant pairwise lod scores were obtained at the flanking markers of SPG4 (maximum lod scores 5.19 and 4.97, correspondingly for markers D2S367 and D2S2230). Sequence analysis of SPG4 revealed a novel frameshift mutation in exon 6 (c.961dupG) resulting in premature termination at the codon 326 (p.Asp321GlyfsX6) ( figure 5 ). The PCR-RFLP analysis showed that the mutation segregates with the disease and the mutation was not found in 200 control chromosomes.
Figure 4
Multipoint logarithm of odds (lod) scores between the disease and markers spanning the SPG38 locus in the RM-36 family Sequence analysis showing the normal SPG4 sequence compared to that with the exon 6 mutation detected in the RM-51 family DISCUSSION We clinically and genetically examined two unrelated Italian families (RM-36 and RM-51) with the cardinal clinical features of SS. As previously reported, 5 our patients also showed significant wasting and weakness of the small hand muscles, primarily of the thenar and sometimes also of the interosseus dorsalis I muscles, foot deformity, or spasticity of the lower limbs to a variable degree. Diagnosis of HSP is more likely than familial amyotrophic lateral sclerosis (ALS) in the two families. First, involvement of cranial motor nerves was never observed in the affected members. Second, the clinical course was relatively benign and none of the patients was bedridden due to muscle weakness at limbs. Third, none of the patients had fasciculations or sufficient abnormalities on EMG for diagnosis of ALS based on the revised El Escorial criteria. 25 Moreover, the presence of family history consistent with AD inheritance, the occurrence of muscle wasting, and the recurrent early age at onset both in lower and upper limbs suggests that primary lateral sclerosis could be clinically distinguished from SS. 26 Interestingly, in one pedigree (RM-36) only the mentioned cardinal clinical features of SS were reported, whereas in the second pedigree (RM-51) a high incidence of patients with a clinical phenotype characterized by typical clinical manifestations of SS had TLE and cognitive dysfunctions. Among the 15 patients we analyzed in the RM-51 family, all of them presented with HSP-SS, 14 with TLE, and 10 with a variable degree of cognitive dysfunctions. Mutations in SPG4 generally lead to pure form of HSP 27 ; nevertheless, high frequency of TLE in patients carrying the SPG4 mutation p.Asp321GlyfsX6 suggests that the epilepsy observed in the family might be due to the mutation per se or to genetic defects in an unknown gene for AD TLE which maps on chromosome 2p22-p21. The association of HSP and epilepsy or cognitive dysfunctions has previously been described [19] [20] [21] [28] [29] [30] [31] [32] [33] [34] and the spectrum of phenotypic manifestations is in agreement with the intrafamilial variability previously described in familial cases of HSP complicated by these neurologic dysfunctions. 19, 21, [28] [29] [30] [31] 33, 34 HS, a maldevelopmental disorder often associated with TLE, 35 was found in all 14 patients with this neurologic condition and, to our knowledge, this is the first report of SS or HSP accompanied by this type of neuropathologic damage. Cortical atrophy was reported in all patients except those of the last generation, possibly because they are presymptomatic. These additional cortical features, which have previously been described for SPG4-HSP, 21 might be useful clinical pointers that this is not typical SS. Besides, the high frequency of HS and cortical atrophy in the patients with SS suggests that genetic defects may lead to these neuropathologic features in addition to neurodegeneration in motor neurons. Involvement of motor neurons in addition to other cortical neuronal populations remind us of presenilin-1 (PS-1) familial Alzheimer disease accompanied by spastic paraplegia. 36 The SPG4 protein (spastin) as well as PS-1 are expressed ubiquitously and spastin has a critical biologic role in the regulation of microtubule (MT) severing, since it assembles into a hexamer containing pore loops which recognize the extreme C terminus of its target protein (tubulin). Investigation of animal models with SPG4-HSP and neuronal expression of both spastin RNA interference and mutant spastin showed that conformational change of the pore loops or absence of hexamer lead to altered stabilization of MT and dysfunction of severing. 37, 38 Truncated and nonfunctional SPG4 protein is probably insufficient for selfassembly or might be degraded by the proteosome pathway. Further biologic studies are necessary to understand whether extended neurodegeneration is due to a single genetic defect or involvement of other genetic or environmental modifiers.
Age at onset in the RM-36 pedigree (SPG38) was earlier and more constant than in SPG17 6, 39, 40 and an impression of genetic anticipation was found in the RM-51 pedigree carrying a novel mutation in SPG4, although the apparent decrease in age at onset might represent an artifact due to enhanced diagnostic sensitivity in each subsequent generation. 9 Neurophysiologic studies of the affected individuals in the two families provided evidence that the disease was not caused only by impairment of the UMN and the data suggested that spinal motor neuron or motor nerve root involvement could cause small hand muscles atrophy since there was no proof of median or ulnar neuropathy. MEP findings were consistent with axonal disease of the pyramidal tract, since all affected individuals of both families presented prolonged CMCTs to the TA. Autoptic examinations might reveal the severity and the distribution of the UMN lesion.
Our genetic analyses in the two families with SS demonstrated two distinct aspects of the disorder: 1) additional locus heterogeneity in SS and 2) involvement of a genetic defect in SPG4. In addition to the previous locus SPG17, a new locus SPG38 has been identified and restricted to a 13.1-cM region on chromosome 4p16-p15, where approximately 84 transcripts have been mapped. Considering the presumed function of currently known HSP genes, 3 two transcripts STX18 and SORCS2 seem to be candidates for SPG38. Both transcripts have a role in intracellular protein trafficking and sorting. Recent molecular studies have demonstrated that HSP genes might interact with each other, e.g., SPG4 and SPG3A 41 or SPG4 and SPG33. 42 Searching for binding protein to HSP genes from the SPG38 region might be a valid approach to identify the causative gene. Furthermore, our study demonstrates that SPG4-HSP may include clinical features observed in SS and widen the spectrum of genetic abnormalities of the disorder.
Re-evaluation of clinical and electrophysiologic features in SPG4 families might demonstrate a phenotype similar to SS.
Our report raises queries regarding the clinicogenetic classification of SS and distal motor neuropathies, given that there is a partial overlap, both clinically and genetically, between SS and dHMN V. In dHMN V, the phenotype is characterized by a distal amyotrophy that starts and predominates in the hands, although patients with SS are characterized by progressive and definite spastic paraparesis, 40, [43] [44] [45] and mutations in the BSCL2 gene cosegregated with the disease, either in SPG17-SS or in dHMN V. Further genotypephenotype studies are needed to realize whether the different phenotypes correlate with the same genetic etiology.
